JP Morgan Chase
AKCA

JP Morgan Chase’s Akcea Therapeutics Inc AKCA Stock Holding History

JP Morgan Chase’s Portfolio AKCA Stock Details AKCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-6,134
Closed -$111K – 6181
2020
Q3 		$111K Buy
6,134
+309
+5% +$4.38K ﹤0.01% 4644
2020
Q2 		$80K Buy
5,825
+1,318
+29% +$20.3K ﹤0.01% 4660
2020
Q1 		$65K Sell
4,507
-920
-17% -$15.1K ﹤0.01% 4658
2019
Q4 		$91K Sell
5,427
-46
-0.8% -$856 ﹤0.01% 4939
2019
Q3 		$84K Buy
5,473
+662
+14% +$14.1K ﹤0.01% 4969
2019
Q2 		$111K Buy
4,811
+186
+4% +$4.59K ﹤0.01% 4892
2019
Q1 		$132K Sell
4,625
-28
-0.6% -$816 ﹤0.01% 4795
2018
Q4 		$140K Buy
4,653
+304
+7% +$8.52K ﹤0.01% 4720
2018
Q3 		$152K Buy
4,349
+31
+0.7% +$938 ﹤0.01% 4790
2018
Q2 		$102K Sell
4,318
-417
-9% -$9.95K ﹤0.01% 4828
2018
Q1 		$121K Sell
4,735
-3,932
-45% -$84.6K ﹤0.01% 4534
2017
Q4 		$150K Buy
8,667
+6,048
+231% +$119K ﹤0.01% 4524
2017
Q3 		$74K Buy
+2,619
New +$48.5K ﹤0.01% 4380

JP Morgan Chase's AKCA Position: Q4 2020 in Review

JP Morgan Chase sold out of Akcea Therapeutics Inc (AKCA) in Q4 2020, closing a stake of 6,134 shares — an estimated $111K sold.

JP Morgan Chase first reported a position in AKCA in Q3 2017 and held it in 13 quarters. The position peaked at $152K in Q3 2018. 0 funds tracked by Wall St. Rank hold AKCA as of Q4 2020.

  • JP Morgan Chase reported no remaining Akcea Therapeutics Inc position as of Q4 2020 after selling out during the quarter.
  • JP Morgan Chase sold 6,134 Akcea Therapeutics Inc shares in Q4 2020, an estimated $111K.
  • JP Morgan Chase first reported a position in Akcea Therapeutics Inc in Q3 2017 and held it in 13 quarters.
  • JP Morgan Chase's Akcea Therapeutics Inc position peaked at $152K in Q3 2018.
  • 0 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q4 2020.

Based on JP Morgan Chase's 13F filing for Q4 2020, filed 11 Feb 2021.